Novus Therapeutics

Novus Therapeutics is a pharmaceutical company focusing on the acquisition, development, and commercialization of ear, nose, and throat (ENT) products.  The company has two technologies, each of which has the potential to be developed for multiple ENT indications.  The company’s lead product is a nasally-administered, combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD), conditions that affect more than 700 million people around the world every year.

biopharmaceuticals
Private
Visit Website
Additional Portfolio Companies
ABAC Therapeutics
Adicet Bio
ArQule
Cathworks
Dynacure
cCAM Biotherapeutics
CheckCap
Eloxx Pharmaceuticals
Enlivex Therapeutics
Entera Bio
Eyevensys
EyeYon
ForSight Vision6 (“V6”)
Horama
Keros Therapeutics
Kite Pharma
Levation Pharma
LogicBio Therapeutics
Metabomed
NovellusDX
Novus Therapeutics
Ocon Medical
Prevail Therapeutics
PACT Pharma
Pi Therapeutics
Protalix
Raziel Therapeutics
ReWalk
VBI Vaccines
Step Pharma
StimatixGI
Sweetch
TargEDys
UroGen
V-Wave
August 27, 2015